Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). The PBC program is on hold. We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information

Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800

Recent News


CymaBay Reports First Quarter 2020 Financial Results and Provides Corporate Update


CymaBay Therapeutics to Report First Quarter 2020 Financial Results on Monday, May 11


CymaBay Therapeutics Comments on Engine Capital Director Nominations

Upcoming Event

Jun 23 2020 10:00 am PT

2020 Annual Meeting of Stockholders

June 23, 2020 at 10:00 am PT

Newark, CA

Q1 2020 Quarterly Results